Trial reportPloS one2007
Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
Trial report in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 63 citations in OpenAlex.
- Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Trial
- Trial
- Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine.PloS one · 2009Trial
- CumulativeFrontiers in cellular and infection microbiology · 2026Article
- The Delay in the Licensing of Protozoal Vaccines: A Comparative History.Frontiers in immunology · 2020Review
- Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model.Immunological reviews · 2020Review
- CD69 Targeting Enhances Anti-vaccinia Virus Immunity.Journal of virology · 2019Article
- Article
- Vaccines against malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Review
- Health providers' perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso.PloS one · 2015Article
- Developments in Viral Vector-Based Vaccines.Vaccines · 2014Review
- CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model.Frontiers in microbiology · 2014Review
- Targeting regulatory T cells to improve vaccine immunogenicity in early life.Frontiers in microbiology · 2014Review
- The influence of delivery vectors on HIV vaccine efficacy.Frontiers in microbiology · 2014Review
- Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites.Frontiers in microbiology · 2014Review
- Immunogenicity, protective efficacy and safety of a recombinant DNA vaccine encoding truncated Plasmodium yoelii sporozoite asparagine-rich protein 1 (PySAP1).Human vaccines & immunotherapeutics · 2013Article
- Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.BioMed research international · 2013Review
- Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Journal of virology · 2012Article
- Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.The Journal of infectious diseases · 2012Article
- A review of malaria vaccine clinical projects based on the WHO rainbow table.Malaria journal · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
background"FFM ME-TRAP" is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara) delivering the pre-erythrocytic malaria antigen ME-TRAP. Over nine months follow-up in our original study, there was no evidence that FFM ME-TRAP provided protection against malaria. The incidence of malaria was slightly higher in children who received FFM ME-TRAP, but this was not statistically significant (hazard ratio 1.5, 95% CI 1.0-2.3). Although the study was unblinded, another nine months follow-up was planned to monitor the incidence of malaria and other serious adverse events. METHODS AND
findings405 children aged 1-6 yrs were initially randomized to vaccination with either FFM ME-TRAP or control (rabies vaccine). 380 children were still available for follow-up after the first nine months. Children were seen weekly and whenever they were unwell for nine months monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to parasitaemia >2,500/microl. During the second nine months monitoring, 49 events met the primary endpoint (febrile malaria with parasites >2,500/microl) in the Intention To Treat (ITT) group. 23 events occurred among the 189 children in the FFM ME-TRAP group, and 26 among the 194 children in the control group. In the full 18 months of monitoring, there were 63 events in the FFM ME-TRAP group and 60 in the control group (HR = 1.2, CI 0.84-1.73, p = 0.35). There was no evidence that the HR changed over the 18 months (test for interaction between time and vaccination p = 0.11).
conclusionsVaccination with FFM ME-TRAP was not protective against malaria in this study. Malaria incidence during 18 months of surveillance was similar in both vaccine groups.
trial registrationControlled-Trials.com ISRCTN88335123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.